PMID- 23537330
OWN - NLM
STAT- MEDLINE
DCOM- 20140110
LR  - 20220408
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 13
DP  - 2013 Mar 28
TI  - Patient self-appraisal of change and minimal clinically important difference on 
      the European organization for the research and treatment of cancer quality of 
      life questionnaire core 30 before and during cancer therapy.
PG  - 165
LID - 10.1186/1471-2407-13-165 [doi]
AB  - BACKGROUND: Clinical interpretation of health related quality of life (HRQOL) 
      scores is challenging. The purpose of this analysis was to interpret score 
      changes and identify minimal clinically important differences (MCID) on the 
      European Organization for Research and Treatment of Cancer Quality of Life 
      Questionnaire-Core 30 (QLQ-C30) before (T1) and during (T2) cancer treatment. 
      METHODS: Patients (N = 627) in stem cell transplant (SCT) and medical (MED) or 
      radiation (RAD) oncology at two comprehensive cancer centers, enrolled in the 
      Electronic Self-Report Assessment-Cancer study and completed the QLQ-C30 at T1 
      and T2. Perceived changes in five QOL domains, physical (PF), emotional (EF), 
      social (SF), cognitive functioning (CF) and global quality of life (QOL), were 
      reported using the Subject Significance Questionnaire (SSQ) at T2. Anchored on 
      SSQ ratings indicating "improvement", "the same", or "deterioration", means and 
      effect sizes were calculated for QLQ-C30 score changes. MCID was calculated as 
      the mean difference in QLQ-C30 score changes reflecting one category change on 
      SSQ rating, using a two-piece linear regression model. RESULTS: A majority of SCT 
      patients (54%) perceived deteriorating global HRQOL versus improvement (17%), 
      while approximately equal proportions of MED/RAD patients perceived improvement 
      (25%) and deterioration (26%). Global QOL decreased 14.2 (SCT) and 2.0 (MED/RAD) 
      units, respectively, among patients reporting "the same" in the SSQ. The MCID 
      ranged 5.7-11.4 (SCT) and 7.2-11.8 (MED/RAD) units among patients reporting 
      deteriorated HRQOL; ranged 2.7-3.4 units among MED/RAD patients reporting 
      improvement. Excepting for the global QOL (MCID =6.9), no meaningful MCID was 
      identified among SCT patients reporting improvement. CONCLUSIONS: Cancer 
      treatment has greater impact on HRQOL among SCT patients than MED/RAD patients. 
      The MCID for QLQ-C30 score change differed across domains, and differed for 
      perceived improvement and deterioration, suggesting different standards for 
      self-evaluating changes in HRQOL during cancer treatment. Specifically, clinical 
      attention can be focused on patients who report at least a 6 point decrease, and 
      for patients who report at least a 3 point increase on QLQ-C30 domains. TRIAL 
      REGISTRATION: The trial was registered with ClinicalTrials.gov: NCT00852852.
FAU - Hong, Fanxing
AU  - Hong F
AD  - Department of Biostatistics and Computational Biology, Dana-Farber Cancer 
      Institute, Harvard School of Public Health, Boston, MA, USA. 
      fxhong@jimmy.harvard.edu
FAU - Bosco, Jaclyn L F
AU  - Bosco JL
FAU - Bush, Nigel
AU  - Bush N
FAU - Berry, Donna L
AU  - Berry DL
LA  - eng
SI  - ClinicalTrials.gov/NCT00852852
GR  - NR008726/NR/NINR NIH HHS/United States
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130328
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cognition
MH  - *Diagnostic Self Evaluation
MH  - Emotions
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*psychology/*therapy
MH  - Quality of Life/*psychology
MH  - Social Participation
MH  - Statistics, Nonparametric
MH  - Stem Cell Transplantation
MH  - Surveys and Questionnaires
MH  - United States
MH  - Young Adult
PMC - PMC3637270
EDAT- 2013/03/30 06:00
MHDA- 2014/01/11 06:00
PMCR- 2013/03/28
CRDT- 2013/03/30 06:00
PHST- 2012/08/13 00:00 [received]
PHST- 2013/03/13 00:00 [accepted]
PHST- 2013/03/30 06:00 [entrez]
PHST- 2013/03/30 06:00 [pubmed]
PHST- 2014/01/11 06:00 [medline]
PHST- 2013/03/28 00:00 [pmc-release]
AID - 1471-2407-13-165 [pii]
AID - 10.1186/1471-2407-13-165 [doi]
PST - epublish
SO  - BMC Cancer. 2013 Mar 28;13:165. doi: 10.1186/1471-2407-13-165.